【商业翻译】锂可降低复发性抑郁症引起的自杀风险（医师报约稿）
这个帖子发布于 18 年零 70 天前，其中的信息可能已发生改变或有所发展。
截稿日期：本星期四上午10点。希望大家能更早点，稿子比较急。
本稿件为《医师报》约稿，署名统一为“丁香”，稿酬按照医师报标准发放。
Lithium cuts suicide risk in recurrent depression
NEW YORK (Reuters Health) - In people suffering from recurrent major depressive disorder, treatment with lithium reduces the risk that they'll commit or attempt suicide, according to a new study
Lithium is commonly used to treat bipolar disorder, or manic depression. Because the drug has shown significant anti-suicide effects in this setting, Dr. Ross J. Baldessarini, of McLean Hospital, Belmont, Massachusetts, and colleagues looked for evidence that it might also benefit patients with recurrent major depression.
As reported in the Journal of Clinical Psychiatry, the investigators identified eight studies that reported on suicides or suicide attempts during treatment with and without lithium in patients with recurrent depression. Their analysis involved a total of 329 subjects.
The overall rate of suicidal acts was 1.48 percent annually among those not given lithium compared with 0.17 percent per year among those treated with lithium -- an 88.5 percent reduction in risk.
"The findings reported here support the conclusion that lithium may represent a useful supplemental or alternative treatment for potentially suicidal patients with recurrent major depressive disorder, as has been found in patients with bipolar disorders," the authors conclude.
SOURCE: Journal of Clinical Psychiatry, March 2007.
本稿件为《医师报》约稿，署名统一为“丁香”，稿酬按照医师报标准发放。
Lithium cuts suicide risk in recurrent depression
NEW YORK (Reuters Health) - In people suffering from recurrent major depressive disorder, treatment with lithium reduces the risk that they'll commit or attempt suicide, according to a new study
Lithium is commonly used to treat bipolar disorder, or manic depression. Because the drug has shown significant anti-suicide effects in this setting, Dr. Ross J. Baldessarini, of McLean Hospital, Belmont, Massachusetts, and colleagues looked for evidence that it might also benefit patients with recurrent major depression.
As reported in the Journal of Clinical Psychiatry, the investigators identified eight studies that reported on suicides or suicide attempts during treatment with and without lithium in patients with recurrent depression. Their analysis involved a total of 329 subjects.
The overall rate of suicidal acts was 1.48 percent annually among those not given lithium compared with 0.17 percent per year among those treated with lithium -- an 88.5 percent reduction in risk.
"The findings reported here support the conclusion that lithium may represent a useful supplemental or alternative treatment for potentially suicidal patients with recurrent major depressive disorder, as has been found in patients with bipolar disorders," the authors conclude.
SOURCE: Journal of Clinical Psychiatry, March 2007.
